8846威尼斯(中国百科)有限公司

临床模式苏州转化医学研究中心产品管线学术文献

Home - 研究开发 - 学术文献

学术文献

临床模式 
苏州转化医学研究中心 
产品管线 
学术文献 

请问您是医疗卫生专业人士吗？

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

发表在：Nature Cancer
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non–small cell lung cancer

发表在：Cancer. 2023;1–13.
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

发表在：Journal of Clinical Oncology 41, no. 16 (June 01, 2023) 3032-3041.
GEMSTONE 304: A Phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

发表在：2023年ESMO世界胃肠道肿瘤大会（ESMO GI）
GEMSTONE-304: a phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

发表在：2023年ESMO世界胃肠道肿瘤大会（ESMO GI）
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GISTs) with different KIT genotypes: post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials

发表在：2023年美国临床肿瘤学会（ASCO）年会
Translational considerations in the development of CS5001, a PBD based ADC against ROR1, a tumor specific target

发表在：2023年第13届世界抗体药物偶联大会(World ADC London)
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study

发表在：The Oncologist, Volume 28, Issue 2, February 2023, Pages 187–e114

1 2 3 4

上一页1/12下一页

声明